RESEARCH ARTICLE

Risk factors for hospitalization among persons with COVID-19—Colorado

Grace M. Vahey1,2*, Emily McDonald1,2, Kristen Marshall1,2,3, Stacey W. Martin1, Helen Chun1, Rachel Herlihy3, Jacqueline E. Tate1, Breanna Kawasaki3, Claire M. Midgley1, Nisha Alden3, Marie E. Killerby1, J. Erin Staples1, on behalf of the Colorado Investigation Team1

1 Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 2 Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 3 Colorado Department of Public Health and Environment, Denver, Colorado, United States of America

¶ Membership of the Colorado Investigation Team is provided in the Acknowledgments

* gvahey@cdc.gov

Abstract

Background

Most current evidence on risk factors for hospitalization because of coronavirus disease 2019 (COVID-19) comes from studies using data abstracted primarily from electronic health records, limited to specific populations, or that fail to capture over-the-counter medications and adjust for potential confounding factors. Properly understanding risk factors for hospitalization will help improve clinical management and facilitate targeted prevention messaging and forecasting and prioritization of clinical and public health resource needs.

Objectives

To identify risk factors for hospitalization using patient questionnaires and chart abstraction.

Methods

We randomly selected 600 of 1,738 laboratory-confirmed Colorado COVID-19 cases with known hospitalization status and illness onset during March 9–31, 2020. In April 2020, we collected demographics, social history, and medications taken in the 30 days before illness onset via telephone questionnaire and collected underlying medical conditions in patient questionnaires and medical record abstraction.

Results

Overall, 364 patients participated; 128 were hospitalized and 236 were non-hospitalized. In multivariable analysis, chronic hypoxemic respiratory failure with oxygen requirement (adjusted odds ratio [aOR] 14.64; 95% confidence interval [CI] 1.45–147.93), taking opioids (aOR 8.05; CI 1.16–55.77), metabolic syndrome (aOR 5.71; CI 1.18–27.54), obesity (aOR 3.35; CI 1.58–7.09), age ≥65 years (aOR 3.22; CI 1.20–7.97), hypertension (aOR 3.14; CI 1.47–6.71), arrhythmia (aOR 2.95; CI 1.00–8.68), and male sex (aOR 2.65; CI 1.44–4.88), were significantly associated with hospitalization.
Conclusion

We identified patient characteristics, medications, and medical conditions, including some novel ones, associated with hospitalization. These data can be used to inform clinical and public health resource needs.

Introduction

Since the first cases of coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were reported from China in late December 2019, the subsequent pandemic has resulted in millions of cases worldwide, including over 33.9 million cases and 600,000 deaths in the United States as of July 18, 2021 [1]. Early descriptions of hospitalized COVID-19 patients from China, Italy, and the United States found that large proportions of patients had underlying medical conditions [2–6]. As the pandemic progressed, many underlying medical conditions have been implicated as potential risk factors for severe COVID-19 illness (e.g., hospitalization, intensive care unit [ICU] admission, intubation, death) including cardiovascular disease, chronic kidney disease, chronic respiratory disease, diabetes mellitus (DM), hypertension, and obesity [7–13]. Patient characteristics, specifically older age, male sex, certain racial or ethnic groups, and smoking history had also been associated with increased risk of severe COVID-19 [11, 12, 14–16]. Additionally, early in the pandemic it was proposed that certain medications, including angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin-receptor blockers (ARBs), and non-steroidal anti-inflammatory drugs (NSAIDs), could enhance SARS-CoV-2 binding and thus increase pathogenicity [17–20]. However, more recent reports have not found this association [21–25].

Early in the pandemic, most evidence on risk factors for hospitalization due to COVID-19 came from retrospective cohort studies and case series that used data abstracted solely from electronic health records [7, 14, 26–35], were limited to specific populations and types of data collected [30–32, 36–42], or failed to adjust for potential confounding factors such as age, sex, or other comorbidities [2, 34, 35, 43]. An improved understanding of factors driving healthcare utilization will inform clinical and public health guidance, facilitate messaging to high-risk groups, and allow for better estimates of clinical and public health resource needs, including preventive (i.e., vaccines), diagnostic, and therapeutic resource allocations. In this case-control study, we use data from interviews and medical record review to identify patient characteristics, underlying medical conditions, and medications that increase the risk of hospitalization among persons with laboratory-confirmed COVID-19.

Methods

Sample

Hospitalized and non-hospitalized patients were identified from laboratory-confirmed COVID-19 cases reported to the Colorado Electronic Disease Reporting System (CEDRS) as of April 5, 2020. Based on data available in CEDRS, patients were considered eligible if they resided in one of nine contiguous counties accounting for ~80% of Colorado’s population (Adams, Arapahoe, Boulder, Denver, Douglas, El Paso, Jefferson, Larimer, and Weld), had known hospitalization status, and self-reported illness onset during March 9–31, 2020 when there was ongoing community transmission and wider availability of SARS-CoV-2 testing in Colorado. To obtain at least 300 patient interviews, including 200 non-hospitalized and 100
hospitalized, we stratified by hospitalization status and used simple random sampling to select 600 patients from 1,738 COVID-19 cases meeting inclusion criteria.

Data collection

At least three attempts were made to contact selected patients on at least two separate days at different times of day during April 10–30, 2020. A standardized questionnaire was administered by telephone to patients who agreed to participate by providing oral consent. Demographic information, social history, underlying medical conditions, and medications and supplements taken in the 30 days prior to illness onset were obtained and hospitalization status and illness onset date from CEDRS were verified. Proxy (e.g., relative or caregiver) interviews were carried out for deceased patients, minors, and persons unable to be interviewed (e.g., those with dementia). Once an interview was complete, medical record abstraction was performed for all patients with records related to their COVID-19 illness available in three electronic medical record repositories covering the major medical systems in the selected counties. A standardized medical record abstraction form was used to collect information on underlying medical conditions and course of illness.

This activity was reviewed by the Centers for Disease Control and Prevention’s (CDC) Human Research Protection Office and determined to be exempt from human participants’ research regulations, including the need for documented written consent, as the activities involved identification, control or prevention of disease in response to an immediate public health threat. It was conducted consistent with applicable federal law and CDC policy (See e.g., 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq.).

Statistical analysis

Data were entered into a Research Electronic Data Capture database [44, 45]. Prescribed and over-the-counter (OTC) medications and supplements taken in the 30 days prior to illness onset were collected as free text during interviews and were categorized into general drug classes by three clinicians (EM, HC, and ES). Participants were considered to have an underlying medical condition if it was reported in either their interview or medical record as the latter has been shown to be a more comprehensive approach to capture these data [46]. Body Mass Index (BMI) was calculated in kg/m$^2$ using height and weight reported in interviews.

Frequencies and percentages were calculated stratified by hospitalization status. Univariable logistic regression was performed to investigate the association of individual patient characteristics, underlying medical conditions, and medications with the outcome of hospitalization; crude odds ratios (OR) and 95% confidence intervals (CI) were calculated. A multivariable logistic regression model for hospitalization was performed to calculate adjusted ORs (aOR) for factors previously reported to be associated with hospitalization or severe disease including age, sex, race, ethnicity, insurance status, smoking status, alcohol use, BMI, hypertension, DM, cardiovascular disease (excluding hypertension), chronic renal disease, and chronic respiratory disease [7–12]. A series of multivariable logistic regression models were then conducted to calculate aORs for individual patient characteristics, medications, and underlying medical conditions adjusted for the previously reported risk factors listed above. When evaluating the association of individual medical conditions of interest within organ system or disease categories with hospitalization, the disease category variable excluded the individual medical condition being evaluated as a risk factor. For example, when calculating the aOR for asthma, the chronic respiratory disease variable included all chronic respiratory diseases except asthma. We assessed collinearity among all variables that were adjusted for in multivariable analysis; no significant collinearity was identified. Univariable and multivariable analyses were only
performed for variables reported by 10 or more patients. Statistical analyses were conducted using SAS 9.4 (SAS Institute Cary, NC) and R version 3.6.3 [47].

Results

Of 600 randomly selected patients, 364 (61%) completed the interview, 46 (8%) were ineligible (i.e., illness onset date prior to March 9 or asymptomatic), 57 (10%) declined to participate, and 133 (22%) were unreachable. Median age of the 364 participating patients was 50 years (range 2 months–94 years), 187 (51%) were male, 279 (77%) identified as White, and 75 (21%) as Hispanic. Almost all (345; 95%) reported having health insurance, and 128 (35%) were hospitalized. Eighteen (5%) patients died, including 15 who were hospitalized and 3 who were not. Compared with patients who declined to participate or were unreachable, participating patients resided proportionately in the same counties, and had similar hospitalization rates (35% versus 31%) and case-fatality ratios (5% vs 8%) but were older than non-participating patients (median age 50 vs 43 years).

Hospitalized patients were older than non-hospitalized patients, with median ages of 61 years (interquartile range [IQR] 48–72 years) and 44 years (IQR 31–57 years), respectively. On univariable analysis when compared to non-hospitalized patients, hospitalized patients more frequently reported being male, having only public health insurance, and having a history of smoking (Table 1). Hospitalized patients less frequently reported current marijuana use or any alcohol consumption within the last year when compared to non-hospitalized patients. Hospitalization status did not differ by race or ethnicity.

Medications that were reportedly taken in the 30 days prior to illness onset among hospitalized patients and non-hospitalized patients are shown in Table 2. Anticoagulants, antihyperglycemics, antihypertensives, cholesterol medications, neuropathic pain treatments, opioids, and pain/fever reducing medications were significantly associated with hospitalization in crude univariable analysis.

Hospitalized patients had a higher median BMI (30; IQR 26–35) than non-hospitalized patients (26; IQR 23–30) and reported more individual underlying medical conditions among all organ systems and disease categories when compared with non-hospitalized patients (Table 3). Chronic lung disease, cardiovascular disease, endocrine disorders, renal disease, liver disease, autoimmune disorders, hematologic disorders, cancer, neurologic or neurodevelopmental disorders, and psychiatric diagnoses were all significantly associated with hospitalization in crude univariable analysis. Immunocompromising conditions were the only broad category not associated with hospitalization status on univariable analysis.

In multivariable analysis, age ≥65 years (aOR 3.22; 95% CI 1.20–7.97) and male sex (aOR 2.65; 95% CI 1.44–4.88) were the only patient characteristics significantly associated with hospitalization (Table 1). Additionally, history of taking opioids (aOR 8.05; 95% CI 1.16–55.77) was significantly associated with hospitalization. Opioids that patients noted taking in the 30 days before their illness onset included buprenorphine, hydrocodone, hydromorphone, morphine, oxycodone, and tramadol. Among underlying medical conditions, chronic hypoxemic respiratory failure with oxygen requirement (aOR 14.64; 95% CI 1.45–147.93), hypertension (aOR 3.14; 95% CI 1.47–6.71), having an arrhythmia (aOR 2.95; 95% CI 1.00–8.68), and obesity (BMI ≥30 kg/m²) (aOR 3.35; 95% CI 1.58–7.09) were significantly associated with hospitalization.

DM was reported as an underlying medical condition for 34 (27%) hospitalized patients and 20 (8%) non-hospitalized patients but was not significantly associated with hospitalization in multivariable analysis. However, when compared to non-hospitalized patients with DM, hospitalized patients with DM were more often ≥65 years old, male, obese, hypertensive, and
Table 1. Demographic characteristics and social behaviors reported in interview among persons with laboratory-confirmed COVID-19, by hospitalization status (n = 364)—Colorado, March 2020.

| Age group, y | Hospitalized (n = 128) | Non-hospitalized (n = 236) | Crude OR¹ (95%CI) | Adjusted OR² (95%CI) |
|--------------|------------------------|---------------------------|------------------|---------------------|
| <18          | 3 (2)                  | 1 (0)                     | -                | -                   |
| 19–44        | 23 (18)                | 118 (50)                  | Reference        | Reference           |
| 45–64        | 50 (39)                | 84 (36)                   | 3.05 (1.73–5.39) | 1.97 (0.99–3.95)    |
| ≥65          | 52 (41)                | 33 (14)                   | 8.08 (4.33–15.09) | 3.22 (1.20–7.97)    |

| Sex          |                         |                           |                  |                     |
|--------------|-------------------------|---------------------------|------------------|---------------------|
| Male         | 79 (62)                 | 108 (46)                  | 1.91 (1.23–2.96) | 2.65 (1.44–4.88)    |
| Female       | 49 (38)                 | 127 (54)                  | Reference        | Reference           |
| Other        | 0 (0)                   | 1 (0)                     | -                | -                   |

| Race         |                         |                           |                  |                     |
|--------------|-------------------------|---------------------------|------------------|---------------------|
| White        | 90 (70)                 | 189 (80)                  | Reference        | Reference           |
| Black        | 13 (10)                 | 12 (5)                    | 2.28 (0.99–5.19) | 1.26 (0.39–4.02)    |
| Asian³       | 8 (6)                   | 8 (3)                     | 2.1 (0.76–5.78)  | -                   |
| Pacific Islander³ | 1 (1) | 1 (0) | - | - |
| American Indian³ | 2 (2) | 1 (0) | - | - |
| Other³       | 5 (4)                   | 17 (7)                    | 0.62 (0.22–1.73) | 1.22 (0.55–2.69)    |
| Unknown      | 4 (3)                   | 4 (2)                     | -                | -                   |
| Multiracial³ | 5 (4)                   | 4 (2)                     | -                | -                   |

| Ethnicity    |                         |                           |                  |                     |
|--------------|-------------------------|---------------------------|------------------|---------------------|
| Non-Hispanic | 86 (67)                 | 163 (69)                  | Reference        | Reference           |
| Hispanic     | 29 (23)                 | 46 (19)                   | 1.2 (0.70–2.04)  | 1.1 (0.53–2.31)     |
| Unknown      | 13 (10)                 | 27 (11)                   | 0.91 (0.45–1.86) | 0.69 (0.24–1.96)    |

| Health insurance |                         |                           |                  |                     |
|------------------|-------------------------|---------------------------|------------------|---------------------|
| Private Insurance | 68 (53)                 | 198 (84)                  | Reference        | Reference           |
| Public Insurance⁴ | 50 (39)                 | 29 (12)                   | 5.02 (2.94–8.56) | 1.8 (0.81–4.00)     |
| Uninsured        | 8 (6)                   | 6 (3)                     | 3.88 (1.30–11.59) | 3.43 (0.80–14.71)   |
| Unknown          | 2 (2)                   | 3 (1)                     | -                | -                   |

| Smoking history |                         |                           |                  |                     |
|-----------------|-------------------------|---------------------------|------------------|---------------------|
| Ever Smoker     | 60 (47)                 | 67 (28)                   | 2.23 (1.42–3.48) | 1.31 (0.72–2.38)    |
| Current Smoker  | 3 (2)                   | 5 (2)                     | -                | -                   |
| Currently Vape  | 3 (2)                   | 9 (4)                     | 0.61 (0.16–2.28) | 0.4 (0.05–2.99)     |

| Current recreational drug use |                         |                           |                  |                     |
|------------------------------|-------------------------|---------------------------|------------------|---------------------|
| Marijuana (THC)              | 6 (5)                   | 32 (14)                   | 0.31 (0.13–0.77) | 1.49 (0.47–4.75)    |
| Inhale                       | 4 (3)                   | 18 (8)                    | 0.39 (0.13–1.18) | 1.48 (0.35–6.27)    |
| Consume                      | 3 (2)                   | 22 (9)                    | 0.23 (0.07–0.80) | 1.64 (0.39–6.97)    |
| Cocaine                      | 0 (0)                   | 2 (1)                     | -                | -                   |
| Methamphetamine             | 1 (1)                   | 0 (0)                     | -                | -                   |
| Heroin                       | 0 (0)                   | 0 (0)                     | -                | -                   |

| Alcohol consumption in the past year |                         |                           |                  |                     |
|--------------------------------------|-------------------------|---------------------------|------------------|---------------------|
| Never                                | 48 (38)                 | 39 (17)                   | Reference        | Reference           |
| ≤ One time per month                 | 31 (24)                 | 53 (22)                   | 0.48 (0.26–0.88) | 0.92 (0.40–2.09)    |
| 2–4 times per month                  | 27 (21)                 | 53 (22)                   | 0.41 (0.22–0.78) | 1.37 (0.57–3.32)    |
| 2–3 times per week                   | 10 (8)                  | 52 (22)                   | 0.16 (0.07–0.35) | 0.42 (0.14–1.23)    |

(Continued)
had at least one other underlying condition adjusted for in our multivariable analysis (32 [94%] versus 11 [55%]) (Fig 1). Finally, patients with metabolic syndrome (the coexistence of DM, hypertension, and obesity) had significantly higher odds of hospitalization in multivariable analysis (aOR 5.71; CI 1.18–27.54).

**Discussion**

Among patients with laboratory-confirmed COVID-19 in Colorado, our analysis found many patient characteristics, underlying medical conditions, and medications to be associated with hospitalization in crude analysis. However, after adjusting for previously described risk factors for severe disease, nine factors were found to be associated with hospitalization due to COVID-19, some that have been previously described (i.e., age, sex, obesity, hypertension, arrhythmia, metabolic syndrome) and others appear to be newly identified (i.e., chronic hypoxemic respiratory failure with oxygen requirement and opioid use). In addition, we did not detect a significant association between hospitalization and some factors that have been previously associated with hospitalization or other indicators of severe COVID-19, including race and ethnicity. Some differences in findings of this analysis and previous reports examining risk factors for severe COVID-19 are expected, due to differences in data collection methods (e.g., interview versus medical record abstraction), measures of disease severity used as outcomes (e.g., hospitalization, ICU admission, mechanical ventilation, or death), and how underlying medical conditions are distributed among different populations and categorized in analyses.

Older age and male sex have been consistently identified as risk factors for hospitalization and severe COVID-19 illness in many studies [7, 8, 13, 14, 27, 29, 48]. The increased risk of poor outcomes among older patients is likely, in part, related to waning immune function that comes with aging [49]. The biologic mechanism causing more severe COVID-19 in males compared to females is unknown but likely multifactorial [12]. The finding of older patients, and in some cases older male patients, having more severe disease is similar to many other viral respiratory diseases (e.g., influenza, SARS, MERS, respiratory syncytial virus) [50–52].

There is increasing evidence of the association between obesity and worse outcomes among persons with COVID-19 [7, 13, 27–30, 36–38, 53]. A dose-dependent effect among classes of obesity was present in our univariable analysis, but because of a large amount of overlap in CIs between classes, they were collapsed to a single ”obese” category for multivariable analysis. Obesity has been linked to the development of several chronic conditions, including sleep apnea, coronary artery disease, type 2 DM, and hypertension [54]. Once we adjusted for obesity in multivariable analysis, several of these related conditions were no longer significantly associated with hospitalization. Since we also adjusted for age in multivariable analysis, the
Table 2. Medications reported in interview to have been taken by persons with laboratory-confirmed COVID-19 in the 30 days prior to illness onset, by hospitalization status (n = 364)—Colorado, March 2020.

| Medication category          | Hospitalized (n = 128) | Non-hospitalized (n = 236) | Crude OR\(^1\) (95%CI) | Adjusted OR\(^2\) (95%CI) |
|------------------------------|------------------------|-----------------------------|-------------------------|---------------------------|
| n (%)                        | n (%)                  |                             |                         |                           |
| Allergy and antihistamine    | 13 (10)                | 19 (8)                      | 1.29 (0.62–2.71)        | 1.01 (0.37–2.75)          |
| Antacid                      | 13 (10)                | 13 (6)                      | 1.93 (0.87–4.32)        | 0.65 (0.21–2.01)          |
| Antiarrhythmic               | 2 (2)                  | 0 (0)                       | --                      | --                        |
| Antibiotic                   | 1 (1)                  | 5 (2)                       | --                      | --                        |
| Anticoagulant/antiplatelet    | 25 (20)                | 14 (6)                      | 3.85 (1.92–7.71)        | 1.04 (0.40–2.65)          |
| Antiemetic                   | 0 (0)                  | 0 (0)                       | --                      | --                        |
| Antiepileptic                | 3 (2)                  | 1 (0)                       | --                      | --                        |
| Antihyperglycemic            | 21 (16)                | 17 (7)                      | 2.53 (1.28–4.99)        | 0.8 (0.22–2.84)           |
| Antihypertensives            | 52 (41)                | 27 (11)                     | 5.29 (3.11–9.03)        | 0.95 (0.37–2.44)          |
| ACE inhibitor                | 19 (15)                | 8 (3)                       | 4.97 (2.11–11.70)       | 0.8 (0.27–2.37)           |
| Angiotensin receptor blocker | 14 (11)                | 6 (3)                       | 4.71 (1.76–12.57)       | 1.5 (0.40–5.62)           |
| Beta blocker                 | 19 (15)                | 8 (3)                       | 4.96 (2.11–11.70)       | 1.24 (0.42–3.69)          |
| Calcium channel blocker      | 15 (12)                | 8 (3)                       | 3.78 (1.56–9.19)        | 1.02 (0.32–3.22)          |
| Thiazide                     | 6 (5)                  | 5 (2)                       | 2.27 (0.68–7.60)        | 0.58 (0.13–2.52)          |
| Other diuretic               | 11 (9)                 | 4 (2)                       | 5.45 (1.70–17.50)       | 2.57 (0.53–12.49)         |
| Other                        | 1 (1)                  | 0 (0)                       | --                      | --                        |
| Antitussive                  | 1 (1)                  | 2 (1)                       | --                      | --                        |
| Antiviral                    | 0 (0)                  | 6 (3)                       | --                      | --                        |
| Asthma treatment (oral)      | 6 (5)                  | 6 (3)                       | 1.89 (0.60–5.97)        | 1.02 (0.21–4.92)          |
| Cancer treatment             | 5 (4)                  | 1 (0)                       | --                      | --                        |
| Cholesterol treatment        | 28 (22)                | 23 (10)                     | 2.59 (1.42–4.73)        | 0.81 (0.34–1.96)          |
| Decongestant                 | 1 (1)                  | 5 (2)                       | --                      | --                        |
| Hormone replacement          | 2 (2)                  | 5 (2)                       | --                      | --                        |
| Hypothyroid treatment        | 10 (8)                 | 12 (5)                      | 1.58 (0.66–3.77)        | 0.57 (0.17–1.94)          |
| Immunosuppressant            | 1 (1)                  | 1 (0)                       | --                      | --                        |
| Inhaler (including inhaled steroids) | 16 (13)                | 19 (8)                      | 1.63 (0.81–3.30)        | 0.83 (0.29–2.42)          |
| Mental health treatment      | 25 (20)                | 36 (15)                     | 1.34 (0.77–2.37)        | 1.41 (0.65–3.08)          |
| Migraine treatment           | 0 (0)                  | 5 (2)                       | --                      | --                        |
| Muscle relaxant              | 6 (5)                  | 3 (1)                       | --                      | --                        |
| Neuropathic pain treatment   | 10 (8)                 | 3 (1)                       | 6.58 (1.78–24.37)       | 1.31 (0.26–6.68)          |
| Nitrates (cardiac)           | 2 (2)                  | 0 (0)                       | --                      | --                        |
| NSAID                        | 27 (21)                | 48 (20)                     | 1.05 (0.62–1.78)        | 0.51 (0.25–1.05)          |
| Opioid                       | 8 (6)                  | 2 (1)                       | 7.8 (1.63–37.31)        | 8.05 (1.16–55.77)         |
| Oral Contraceptive           | 0 (0)                  | 14 (6)                      | --                      | --                        |
| Pain medication/fever reducer | 26 (20)                | 26 (11)                     | 2.06 (1.14–3.72)        | 1.63 (0.71–3.70)          |
| Phosphodiesterase-5 enzyme inhibitor | 0 (0)               | 0 (0)                       | --                      | --                        |
| Steroids                     | 4 (3)                  | 3 (1)                       | --                      | --                        |
| Topical                      | 0 (0)                  | 1 (0)                       | --                      | --                        |
| Vitamins and supplements     | 54 (42)                | 107 (45)                    | 0.88 (0.57–1.36)        | 0.72 (0.40–1.30)          |

**Abbreviations:** CI—confidence interval; OR—odds ratio.

\(^1\)Exact methods were used in crude analysis if there was one or more expected cell count less than 5.

\(^2\)Multivariable model used for adjustment included age, sex, race, ethnicity, insurance status, smoking history, alcohol use, BMI, hypertension, diabetes, cardiovascular disease, chronic renal disease, and chronic respiratory disease.

https://doi.org/10.1371/journal.pone.0256917.t002
Table 3. Underlying medical conditions reported in interviews or medical records among persons with laboratory-confirmed COVID-19, by hospitalization status (n = 364)—Colorado, March 2020.

| Condition                                      | Hospitalized (n = 128) | Non-hospitalized (n = 236) | Crude OR^1 (95%CI) | Adjusted OR^2 (95%CI) |
|------------------------------------------------|------------------------|----------------------------|---------------------|-----------------------|
| Cardiovascular disease                         | n (%)                  | n (%)                      |                     |                       |
| Hypertension                                   | 75 (59)                | 49 (21)                    | 5.4 (3.37–8.66)     | 1.11 (0.51–2.43)      |
| Coronary artery disease, heart attack          | 68 (53)                | 29 (12)                    | 8.09 (4.80–13.62)   | 3.14 (1.47–6.71)      |
| Heart failure, congestive heart failure        | 9 (7)                  | 1 (0)                      | 17.77 (2.23–141.94) | 2.47 (0.25–24.85)     |
| Cerebrovascular accident, stroke               | 3 (2)                  | 3 (1)                      | -                   | -                     |
| Congenital heart disease                       | 0 (0)                  | 1 (0)                      | -                   | -                     |
| Valvular heart disease                         | 2 (2)                  | 1 (0)                      | -                   | -                     |
| Arrhythmia                                     | 17 (13)                | 10 (4)                     | 3.46 (1.53–7.81)    | 2.95 (1.00–8.68)      |
| Hyperlipidemia\(^3\)                           | 27 (21)                | 8 (3)                      | -                   | -                     |
| Chronic lung disease                           | 56 (44)                | 51 (22)                    | 2.82 (1.77–4.50)    | 1.82 (0.97–3.39)      |
| Asthma or reactive airway disease              | 24 (19)                | 36 (15)                    | 1.28 (0.73–2.26)    | 1.17 (0.54–2.54)      |
| Emphysema, COPD, or chronic bronchitis         | 18 (14)                | 6 (3)                      | 6.27 (2.42–16.24)   | 3.01 (0.80–11.31)     |
| Interstitial lung disease                      | 0 (0)                  | 0 (0)                      | -                   | -                     |
| Pulmonary fibrosis                             | 1 (1)                  | 0 (0)                      | -                   | -                     |
| Restrictive lung disease                       | 3 (2)                  | 1 (0)                      | -                   | -                     |
| Sarcoidosis                                    | 0 (0)                  | 0 (0)                      | -                   | -                     |
| Cystic fibrosis                                | 0 (0)                  | 0 (0)                      | -                   | -                     |
| Chronic hypoxemic respiratory failure with oxygen requirement | 13 (10)                | 1 (0)                      | 26.57 (3.43–205.56) | 14.64 (1.45–147.93)  |
| Obstructive sleep apnea                        | 18 (14)                | 10 (4)                     | 3.7 (1.65–8.28)     | 0.67 (0.23–1.97)      |
| Active tuberculosis                            | 1 (1)                  | 2 (1)                      | -                   | -                     |
| Endocrine disorder                             | 65 (51)                | 54 (23)                    | 3.48 (2.19–5.51)    | 1.81 (0.91–3.59)      |
| Diabetes Mellitus                              | 34 (27)                | 20 (8)                     | 3.9 (2.14–7.14)     | 1.08 (0.45–2.61)      |
| Pre-diabetes                                   | 10 (8)                 | 13 (6)                     | 1.45 (0.62–3.42)    | 0.9 (0.31–2.57)       |
| Hypothyroidium\(^3\)                          | 18 (14)                | 15 (6)                     | -                   | -                     |
| Renal disease                                  | 25 (20)                | 11 (5)                     | 4.96 (2.35–10.47)   | 1.71 (0.62–4.70)      |
| Chronic kidney disease or insufficiency        | 13 (10)                | 5 (2)                      | 5.22 (1.82–15.00)   | 0.66 (0.15–2.91)      |
| End-stage renal disease                        | 5 (4)                  | 0 (0)                      | -                   | -                     |
| Dialysis                                       | 4 (3)                  | 0 (0)                      | -                   | -                     |
| Hemodialysis                                   | 3 (2)                  | 0 (0)                      | -                   | -                     |
| Peritoneal                                     | 1 (1)                  | 0 (0)                      | -                   | -                     |
| Liver disease                                  | 9 (7)                  | 4 (2)                      | 4.39 (1.32–14.54)   | 2.21 (0.49–10.04)     |
| Alcoholic hepatitis                            | 0 (0)                  | 0 (0)                      | -                   | -                     |
| Chronic liver disease                          | 0 (0)                  | 0 (0)                      | -                   | -                     |
| Cirrhosis or end stage liver disease           | 1 (1)                  | 0 (0)                      | -                   | -                     |
| Hepatitis B, chronic                           | 1 (1)                  | 0 (0)                      | -                   | -                     |
| Hepatitis C, chronic                           | 1 (1)                  | 0 (0)                      | -                   | -                     |
| Non-alcoholic fatty liver disease              | 2 (2)                  | 3 (1)                      | -                   | -                     |
| Autoimmune disorder                            | 13 (10)                | 11 (5)                     | 2.31 (1.00–5.32)    | 2.58 (0.82–8.16)      |
| Rheumatoid arthritis                           | 4 (3)                  | 2 (1)                      | -                   | -                     |
| Systemic lupus                                 | 1 (1)                  | 1 (0)                      | -                   | -                     |
| Hematologic disorder                           | 21 (16)                | 14 (6)                     | 3.11 (1.52–6.36)    | 2.18 (0.88–5.43)      |
| Anemia                                         | 13 (10)                | 7 (3)                      | 3.7 (1.43–9.52)     | 2.04 (0.56–7.44)      |
| Sickle cell disease                            | 0 (0)                  | 0 (0)                      | -                   | -                     |
| Sickle cell trait                              | 0 (0)                  | 0 (0)                      | -                   | -                     |
| Bleeding or clotting disorder                  | 5 (4)                  | 2 (1)                      | -                   | -                     |
| Immunocompromised condition                    | 9 (7)                  | 10 (4)                     | 1.71 (0.68–4.32)    | 1.42 (0.39–5.11)      |
| HIV infection                                  | 0 (0)                  | 1 (0)                      | -                   | -                     |

(Continued)
association between hospitalization and obesity suggests that patients with obesity are more likely to be hospitalized, regardless of age, which has been found by others [32, 36].

While cardiovascular disease, a category inclusive of multiple individual conditions, has been identified as a risk factor for hospitalization and severe COVID-19 [2, 10, 15], it was not

| Table 3. (Continued) |
|-----------------------|
|                      | Hospitalized (n = 128) | Non-hospitalized (n = 236) | Crude OR² (95%CI) | Adjusted OR² (95%CI) |
| AIDS                  | 0 (0)                  | 0 (0)                      | -                | -                |
| Solid organ transplant| 3 (2)                  | 0 (0)                      | -                | -                |
| Stem cell transplant  | 0 (0)                  | 0 (0)                      | -                | -                |
| Leukemia              | 1 (1)                  | 1 (0)                      | -                | -                |
| Lymphoma              | 0 (0)                  | 1 (0)                      | -                | -                |
| Multiple myeloma      | 1 (1)                  | 0 (0)                      | -                | -                |
| Splenectomy or asplenia| 0 (0)               | 2 (1)                      | -                | -                |
| Cancer                | 22 (17)                | 18 (8)                     | 2.51 (1.29–4.89) | 1.6 (0.66–3.86) |
| IV chemotherapy       | 6 (5)                  | 5 (2)                      | 2.27 (0.68–7.60) | 2.79 (0.57–13.65)|
| Oral chemotherapy     | 1 (1)                  | 2 (1)                      | -                | -                |
| Radiation             | 6 (5)                  | 6 (3)                      | 1.89 (0.60–5.97) | 1.51 (0.36–6.35)|
| Other                 | 12 (9)                 | 9 (4)                      | 2.61 (1.07–6.37) | 1.86 (0.55–6.31)|
| Neurologic or neurodevelopmental disorder | 27 (21) | 16 (7) | 3.68 (1.90–7.12) | 1.61 (0.66–3.92)|
| Migraines³            | 3 (2)                  | 11 (5)                     | -                | -                |
| Dementia³             | 4 (3)                  | 5 (2)                      | -                | -                |
| Psychiatric diagnosis | 40 (31)                | 49 (21)                    | 1.73 (1.06–2.83) | 1.17 (0.58–2.36)|
| Other chronic diseases| 78 (61)                | 51 (22)                    | -                | -                |
| Gastroesophageal reflux disease³ | 20 (16) | 5 (2) | -                | -                |
| Allergic rhinitis³    | 8 (6)                  | 11 (5)                     | -                | -                |
| Arthritis³            | 14 (11)                | 5 (2)                      | -                | -                |
| Chronic pain³         | 7 (5)                  | 1 (0)                      | -                | -                |
| Benign prostatic hyperplasia³ | 7 (5)    | 0 (0)                         | -                | -                |
| Bone density abnormality³ | 2 (2)            | 4 (2)                      | -                | -                |
| BMI⁴ (kg/m²)          |                       |                            |                  |                  |
| Underweight (<18.5)   | 3 (2)                  | 1 (0)                      | -                | -                |
| Normal (18.5 to <25)  | 23 (18)                | 93 (39)                    | Reference        | Reference        |
| Overweight (25 to <30) | 31 (24)               | 85 (36)                    | 1.48 (0.80–2.73) | 0.66 (0.29–1.49)|
| Obese (≥30)           | 67 (52)                | 54 (23)                    | 5.02 (2.81–8.96) | 3.35 (1.58–7.09)|
| Class 1 (30 to <35)   | 38 (30)                | 34 (14)                    | 4.52 (2.36–8.66) | -                |
| Class 2 (35 to <40)   | 20 (16)                | 15 (6)                     | 5.39 (2.40–12.12)| -                |
| Class 3 (≥40)         | 9 (7)                  | 5 (2)                      | 7.28 (2.23–23.80)| -                |
| Unknown               | 4 (3)                  | 3 (1)                      | -                | -                |
| Metabolic Syndrome⁵   | 19 (15)                | 2 (1)                      | 20.39 (4.67–89.11) | 5.71 (1.18–27.54)|

Abbreviations: CI–confidence interval; OR–odds ratio.
1 Exact methods were used in crude analysis if there was one or more expected cell count less than 5.
2 Multivariable model used for adjustment included age, sex, race, ethnicity, insurance status, ever smoking, alcohol use, BMI, hypertension, diabetes, cardiovascular disease, chronic renal disease, and chronic respiratory disease.
3 These variables were categorized from free text responses to “Other” chronic disease answers. Because they were not collected systematically like the other underlying medical conditions, descriptive statistics alone are reported.
4 Body mass index (BMI) was calculated from height and weight reported during interviews.
5 Multivariable model when investigating metabolic syndrome did not include individual hypertension, diabetes, and BMI variables.

https://doi.org/10.1371/journal.pone.0256917.t003
statistically significant in our multivariable analysis. Previous reports have found individual cardiac conditions (e.g., congestive heart failure, coronary artery disease, atrial fibrillation/arrhythmia, and hypertension) to be associated with hospitalization [7, 26, 27, 33, 41–43, 55]. Within this disease category, we found that history of hypertension or arrhythmia was associated with increased risk of hospitalization in multivariable analysis. However, we did not capture information regarding the severity (e.g., stage) or control of hypertension so we do not know how much of our observed effect might be because of uncontrolled hypertension.

Despite an observed higher frequency of hyperlipidemia in hospitalized participants, we did not evaluate its association with hospitalization given the condition was reported in a free text field, reported less frequently during interviews, and many non-hospitalized patients had limited or no medical records available for review. However, in the few studies that systematically collected hyperlipidemia through chart review, patients with hyperlipidemia were less or similarly likely to be hospitalized with COVID-19 [6, 56].

Similar to cardiovascular disease, chronic respiratory disease as a category was not significantly associated with hospitalization in multivariable analysis. There is mixed evidence in the literature regarding chronic respiratory disease as a risk factor for hospitalization and severe COVID-19 [7, 8], which could be related to chronic respiratory disease being a diverse group of conditions that occur in different demographics groups and individual diseases might have different associations with COVID-19 outcomes. For instance, some evaluations found chronic obstructive pulmonary disease (COPD) associated with worse COVID-19 outcomes, while asthma was often found to have no or a protective association with worse COVID-19 outcomes [31, 38, 41, 42]. Although we did not find COPD to be associated with hospitalization, our analysis identified 13/14 individuals with chronic hypoxemic respiratory failure with
an oxygen requirement in this investigation were hospitalized. This finding is not surprising but suggests that the severity of underlying medical conditions might further influence their association with COVID-19 hospitalization. While smoking was associated with hospitalization in crude analysis, it was not significant in multivariable analysis. Findings of previous studies of smoking and COVID-19 outcomes have been mixed, including increased, decreased, or no impact on risk as was found in this analysis [16, 39, 57–59]. Smoking has also been found to cause variable risk for SARS-CoV-2 infection suggesting a potential complex effect [60].

In our multivariable analysis, DM was not significantly associated with hospitalization despite being significantly associated in crude analysis. However, when DM was evaluated as part of metabolic syndrome, the syndrome was significantly associated with hospitalization suggesting that DM might only be a risk factor for hospitalization when in combination with other underlying conditions. Metabolic syndrome has been found, in at least one other study, to be associated with multiple negative outcomes among hospitalized COVID-19 patients [61]. We did not differentiate between type 1 and type 2 DM in our analysis, so we are unable to determine if the relationship between DM and COVID-19 hospitalization varies by type. Additionally, we had a lower number of patients with DM, which might have reduced our power to detect an association in multivariable analysis, as was reported in at least one other study [35] compared to studies where DM was reported to occur at a higher frequency and was found to be a risk factor for hospitalization [7, 27, 29, 30, 34, 48, 55, 56]. Compared to other U.S. states, Colorado’s population is relatively healthy having the lowest proportion of adults with obesity and the fourth lowest percentage of residents with at least one of six underlying medical conditions found to be associated with an increased COVID-19 case fatality ratio in China [62, 63].

Race and ethnicity were not found to be significantly associated with hospitalization in this analysis, in contrast to other reports that found persons of Black race [13–15, 26, 29–31, 40, 64] or Hispanic ethnicity [7, 33] had worse COVID-19 outcomes. Overall, we had a small number of Black participants in this analysis, which is consistent with the racial makeup of Colorado [65], and likely substantially limited our ability to identify an association between Black persons and hospitalization. Our cohort had a notable proportion (20%) of participants who identified as Hispanic, which is also consistent with the Colorado population [65]. Of at least five previously published U.S. cohort studies that reported ethnicity, two found an association between persons of Hispanic ethnicity and hospitalization due to COVID-19 [7, 33]. Both studies included >5,000 participants of whom 25–49% were Hispanic compared to the three other studies and our own that had <2,000 participants of whom 15–28% were Hispanic [26, 30, 31]. This suggests that the association between persons of Hispanic ethnicity and hospitalization due to COVID-19 might only be detected in large cohort studies.

One of the unique attributes of this evaluation is the collection of medication and supplement use from patient interviews, which allowed for exploration of the use of prescribed and OTC medications taken in the 30 days prior to COVID-19 symptom onset and their association with hospitalization. It has been hypothesized that patients taking ACE inhibitors or ARBs might be at increased risk for more severe COVID-19 based on SARS-CoV-2 binding to ACE2 receptors found on epithelial cells in the respiratory tract as well as in intestine, kidney, and blood vessels [17, 18, 66, 67]. In our analysis, a larger proportion of hospitalized patients reported taking ACE inhibitors and ARBs than non-hospitalized patients, but the difference was not significant after adjusting for several factors, including age and hypertension, in multivariable analysis. This finding is consistent with several other analyses examining ACE inhibitor and/or ARB use as risk factors for worse COVID-19 outcomes, including at least one that suggests a protective effect against adverse COVID-19 outcomes [21–25, 68]. We also did not detect an association with NSAID use in the 30 days prior to illness onset and hospitalization.
due to COVID-19, despite previous concerns regarding NSAIDs use and increased risk of worse COVID-19 outcomes [18, 20].

Although no association was seen with ACE inhibitor, ARB, or NSAID use, an association between hospitalization due to COVID-19 and reported opioid use in the 30 days prior to illness onset was observed. Several mechanisms have been proposed for how opioids might cause worse COVID-19 outcomes, including respiratory depression, suppression of immune function, and drug interactions [69]. Given the small number of participants reporting taking these medications and resulting wide confidence intervals, the actual magnitude of the association cannot be predicted with certainty. However, this potential association between COVID-19 and medications that might interfere with respiratory and immune function deserves further evaluation, particularly given the current opioid epidemic in the United States [70].

This investigation is subject to multiple limitations. First, interviews were conducted several weeks after illness onset, which allowed for accurate classification of patients by hospitalization status but might have led to recall bias. However, time between illness onset and interview did not differ by hospitalization status so any existing recall bias should not significantly influence associations with hospitalization. Second, non-hospitalized participants were less likely to have medical records related to their COVID-19 illness available for abstraction (n = 88 or 37% of non-hospitalized patients had records available for review) biasing the number of underlying medical conditions reported towards those who were hospitalized. Third, BMI was calculated using self-reported height and weight. Given the tendency for people to under-report their weight, and the higher degree of under-reporting among those in higher BMI categories, the actual association between obesity and severe disease might be underestimated [71]. Fourth, our findings are specific to this population and might not be generalizable to all populations due to the evolution of testing practices and characteristics of infected persons during the pandemic, socioeconomic status, or underlying health status of participants [42]. Fifth, because many demographic or social characteristics, specific underlying medical conditions, and medications were reported by a small number of participants, our ability to make conclusions about their associations with hospitalization was limited and confidence intervals for some estimates were wide. This also prevented adequate exploration and adjustment for interaction between potential risk factors. Lastly, because data were partly self-reported, there is a possibility of response bias.

In this analysis, age ≥65 years, male sex, obesity, hypertension, chronic hypoxemic respiratory failure with an oxygen requirement, arrhythmia, metabolic syndrome, and opioid use were determined to be independent risk factors for hospitalization among COVID-19 patients in Colorado. Understanding risk factors for hospitalization can inform strategic planning and resource allocation at multiple levels including prevention (e.g., vaccine allocation), diagnosis, and treatment. Given the unique findings of this analysis as well as conflicting findings among published studies, further analyses with larger sample sizes of persons from diverse backgrounds throughout the U.S. and worldwide could help build consensus in our understanding of what patient characteristics, medications, and underlying medical conditions are associated with hospitalization and worse outcomes in persons with COVID-19. Persons in high risk groups should be targeted for tailored public health messaging, prioritized for preventive measures, and should receive appropriate clinical management as soon as possible after developing symptoms compatible with COVID-19. It is important to remember that all persons, regardless of demographics, medication use, and underlying medical conditions are at risk for severe COVID-19 illness and should take all recommended precautions to prevent infection and transmission including mask wearing, social distancing, and hand hygiene.
Acknowledgments

Colorado investigations team: Alison J. Basile; Alyssa R. Beck; Karen L. Boroughs; Anna Bowen; Paul L. Burns; Cathy L. Buschmeier; Nathaniel M. Byers; Amanda E. Calvert; Trudy V. Chambers; David T. Dennis; Mary Ellen Fernandez; Katherine T. Ficalora; Kelly A. Fitzpatrick; Shannon Fleck-Derderian; Erik S. Foster; Christin H. Goodman; Carolyn V. Gould; Garrett Heck; Claire Y.-H. Huang; Amy J. Lambert; Aine Lehane; Jennifer A. Lehman; Kristine Lindell; Nicole P. Lindsey*; Sarah E. Maes; Courtney C. Nawrocki; Nancy H. Nay; Kathleen A. Orloski; Lynn Osikowicz; Christina Parise; Sara C. Perinet; Mark A. Pilgard; Jordan A. Powers; Maria F. Rizzo; Brandy J. Russell; Tracey M. Semcer; Benjamin Skinner; Melanie Spillane; Julie Thwing

*Author group lead. Email: nplindsey@cdc.gov

The authors would like to thank Sarabeth Mathis for her assistance with database development and CDC Emergency Operation Center staff for facilitating deployment of personnel and equipment for this investigation.

Disclaimer: The findings and conclusion in this report are those of the authors and do not necessarily represent the official position of the CDC.

Author Contributions

Conceptualization: Grace M. Vahey, Emily McDonald, Kristen Marshall, Rachel Herlihy, Jacqueline E. Tate, Breanna Kawasaki, Claire M. Midgley, Marie E. Killerby, J. Erin Staples.

Data curation: Grace M. Vahey, Emily McDonald, Kristen Marshall, Stacey W. Martin, Helen Chun, Jacqueline E. Tate, Claire M. Midgley, Marie E. Killerby, J. Erin Staples.

Formal analysis: Grace M. Vahey, Stacey W. Martin, Helen Chun, Marie E. Killerby.

Investigation: Kristen Marshall, Helen Chun, Breanna Kawasaki, J. Erin Staples.

Methodology: Emily McDonald, Kristen Marshall, Jacqueline E. Tate, J. Erin Staples.

Resources: Rachel Herlihy, Jacqueline E. Tate, Breanna Kawasaki, Claire M. Midgley, Nisha Alden, Marie E. Killerby, J. Erin Staples.

Supervision: Rachel Herlihy, Jacqueline E. Tate, Claire M. Midgley, J. Erin Staples.

Visualization: Grace M. Vahey.

Writing – original draft: Grace M. Vahey, J. Erin Staples.

Writing – review & editing: Grace M. Vahey, Emily McDonald, Kristen Marshall, Stacey W. Martin, Helen Chun, Rachel Herlihy, Jacqueline E. Tate, Breanna Kawasaki, Claire M. Midgley, Nisha Alden, Marie E. Killerby, J. Erin Staples.

References

1. Centers for Disease Control and Prevention. CDC Coronavirus Disease 2019 (COVID-19) Cases in the U.S. 2020. Accessed at https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html on 20 November 2020.

2. CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019—United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 3; 69(13):382–386. https://doi.org/10.15585/mmwr.mm6913e2 PMID: 32240123

3. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 Apr 6; 323(16):1574–81. https://doi.org/10.1001/jama.2020.5394 Epub ahead of print. PMID: 32250385
4. Guan WJ, Ni ZY, Hu Y, et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30; 382(18):1708–1720. https://doi.org/10.1056/NEJMoA2002032 Epub 2020 Feb 28. PMID: 32109013

5. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019—COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 17; 69(15):458–464. https://doi.org/10.15585/mmwr. mm6915e3 PMID: 32296251

6. Polverino F, Stern DA, Ruocco G, et al. ItaliCO study group. Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO). Front Cardiovasc Med. 2020 Oct 9; 7:585866. https://doi.org/10.3389/fcvm.2020.585866 Erratum in: Front Cardiovasc Med. 2020 Dec 09;7:631602. PMID: 33195473

7. Petritti CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020 May 22; 369:m1966. https://doi.org/10.1136/bmj.m1966 PMID: 32444366

8. Chen R, Liang W, Jiang M, et al. Medical Treatment Expert Group for COVID-19. Risk Factors of Fatal COVID-19 —Georgia, March 2020. MMWR Morb Mortal Wkly Rep. 2020 May 8; 69(18):545–550. https://doi.org/10.15585/mmwr.mm6918e1 PMID: 32379729

9. Jutzeler CR, Bourguignon L, Weis CV, et al. Comorbidities, clinical signs and symptoms, laboratory findings, imaging features, treatment strategies, and outcomes in adult and pediatric patients with COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020 Aug 4; 37:101825. https://doi.org/10.1016/j.tmaid.2020.101825 Epub ahead of print. PMID: 32763496

10. Ko JY, Danielson ML, Town M, et al. COVID-NET Surveillance Team. Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System. Clin Infect Dis. 2021 Jun 1; 72(11):e895–e703. https://doi.org/10.1093/cid/ciaa1419 PMID: 32945846

11. Price-Haywood EG, Burton J, Fort D, et al. Hospitalization and Mortality among Black Patients and White Patients with Covid-19. N Engl J Med. 2020 Jun 25; 382(26):2534–2543. https://doi.org/10.1056/NEJMsa2011686 Epub 2020 May 27. PMID: 32459916

12. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020 Aug; 584(7821):430–436. https://doi.org/10.1038/s41586-020-2521-4 Epub 2020 Jul 8. PMID: 32640463

13. Reddy RK, Charles WN, Sklavounos A, et al. The effect of smoking on COVID-19 severity: A systematic review and meta-analysis. J Med Virol. 2020 Aug 4;10.1002/jmv.26389 Epub ahead of print. PMID: 32749705

14. Liabeuf S, Moragny J, Bennis Y, et al. Association between renin-angiotensin system inhibitors and COVID-19 complications. Eur Heart J Cardiovasc Pharmacother. 2020 Jun 12;pvaa062. https://doi.org/10.1093/ehjcvp/pvaa062 Epub ahead of print. PMID: 32531040

15. Fang L, Karakulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020 Apr; 8(4):e21. https://doi.org/10.1016/S2213-2600(20)30116-8 Epub 2020 Mar 11. Erratum in: Lancet Respir Med. 2020 Jun;8(6):e54. PMID: 32171062

16. Little P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ. 2020 Mar 27; 368:m1185. https://doi.org/10.1136/bmj.m1185 PMID: 32208665

17. Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ. 2020 Mar 17; 369:m1086. https://doi.org/10.1136/bmj.m1086 PMID: 32184201

18. Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med. 2020 Jun 18; 382(25):2441–2448. https://doi.org/10.1056/NEJMoA2008975 Epub 2020 May 1. PMID: 32356629
23. Raisi-Estabragh Z, McCracken C, Ardissino M, et al. Renin-Angiotensin-Aldosterone System Blockers Are Not Associated With Coronavirus Disease 2019 (COVID-19) Hospitalization: Study of 1,439 UK Biobank Cases. Front Cardiovasc Med. 2020 Jul 14; 7:138. https://doi.org/10.3389/fcvm.2020.00138 PMID: 32766285

24. Hippisley-Cox J, Young D, Coupland C, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart. 2020 Jul 31:heartjn-2020-317393. https://doi.org/10.1136/heartjn-2020-317393 Epub ahead of print. PMID: 32737124

25. Chen R, Yang J, Gao X, et al. Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension. J Clin Hypertens (Greenwich). 2020 Oct 2;10.1111/jch.14038. https://doi.org/10.1111/jch.14038 Epub ahead of print. PMID: 33006442

26. Azar KMJ, Shen Z, Romanelli RJ, et al. Disparities In Outcomes Among COVID-19 Patients In A Large Health Care System In California. Health Aff (Millwood). 2020 Jul; 39(7):1253–1262. https://doi.org/10.1377/hltha ff.2020.00598 Epub 2020 May 21. PMID: 32437224

27. van Gerven M, Alsen M, Little C, et al. Risk factors and outcomes of COVID-19 in New York City; a retrospective cohort study. J Med Virol. 2020 Jul 24;10.1002/jmv.26337. https://doi.org/10.1002/jmv.26337 Epub ahead of print. PMID: 32706392

28. Imam Z, Odish F, Armstrong J, et al. Independent Correlates of Hospitalization in 2040 Patients with COVID-19 at a Large Hospital System in Michigan, United States. J Gen Intern Med. 2020 Aug; 35 (6):2516–2517. https://doi.org/10.1007/s11606-020-05937-5 Epub 2020 Jun 9. PMID: 32519526

29. Killerby ME, Link-Gelles R, Haight SC, et al. CDC COVID-19 Response Clinical Team. Characteristics Associated with Hospitalization Among Patients with COVID-19—Metropolitan Atlanta, Georgia, March-April 2020. MMWR Morb Mortal Wkly Rep. 2020 Jun 26; 69(25):790–794. https://doi.org/10.15585/mmwr.mm6925e1 PMID: 32584797

30. Ebinger JE, Achamniallah N, Ji H, et al. Pre-existing traits associated with Covid-19 illness severity. PLoS One. 2020 Jul 23; 15(7):e0236240. https://doi.org/10.1371/journal.pone.0236240 PMID: 32702044

31. Wang L, Foer D, Bates DW, et al. Risk factors for hospitalization, intensive care, and mortality among patients with asthma and COVID-19. J Allergy Clin Immunol. 2020 Jul 29:S0091-6749(20)31039-3. https://doi.org/10.1016/j.jaci.2020.07.018 Epub ahead of print. PMID: 32735807

32. Steinberg E, Wright E, Kushner B. In Young Adults with COVID-19, Obesity Is Associated with Adverse Outcomes. West J Emerg Med. 2020 Jun 15; 21(4):752–755. https://doi.org/10.5811/westjem.2020.5.47972 PMID: 32726235

33. Gottlieb M, Sansom S, Frankenberger C, Ward E, Hota B. Clinical Course and Factors Associated With Hospitalization and Critical Illness Among COVID-19 Patients in Chicago, Illinois. Acad Emerg Med. 2020 Aug 6;https://doi.org/10.1111/acem.14104 PMID: 32762106

34. Suleyman G, Fadel RA, Malette KM, et al. Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. JAMA Netw Open. 2020 Jun 1; 3 (6):e2012270. https://doi.org/10.1001/jamanetworkopen.2020.12270 PMID: 32543702

35. Sisó-Almirall A, Kostov B, Mas-Heredia M, et al. Prognostic factors in Spanish COVID-19 patients: A case series from Barcelona. PLoS One. 2020 Aug 21; 15(8):e0237960. https://doi.org/10.1371/journal.pone.0237960 PMID: 32822413

36. Lighter J, Phillips M, Hochman S, et al. Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission. Clin Infect Dis. 2020 Jul 28; 71(15):896–897. https://doi.org/10.1093/cid/ciaa415 PMID: 32271368

37. Harmer M, Gale CR, Kivimäki M, et al. Overweight, obesity, and risk of hospitalization for COVID-19: A community-based cohort study of adults in the United Kingdom. Proc Natl Acad Sci U S A. 2020 Sep 1; 117(35):21011–21013. https://doi.org/10.1073/pnas.2011086117 Epub 2020 Aug 11. PMID: 32788355

38. Giannouchos TV, Sussman RA, Mier JM, et al. Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory-confirmed COVID-19 cases. Eur Respir J. 2020 Jul 30;2002144. https://doi.org/10.1183/13993003.02144–2020 Epub ahead of print.

39. Hernández-Galdamez DR, González-Block MA, Romo-Dueñas DK, et al. Increased Risk of Hospitalization and Death in Patients with COVID-19 and Pre-existing Noncommunicable Diseases and Modifiable Risk Factors in Mexico. Arch Med Res. 2020 Jul 22:S0188-4409(20)30722-0. https://doi.org/10.1016/j.arcmed.2020.07.003 Epub ahead of print. PMID: 32747155

40. Patel AP, Paranjpe MD, Kathiresan NP, et al. Race, socioeconomic deprivation, and hospitalization for COVID-19 in English participants of a national biobank. Int J Equity Health. 2020 Jul 6; 19(1):114. https://doi.org/10.1186/s12939-020-01227-y PMID: 32631328

41. Atkins JL, Masoli JAH, Delgado J, et al. Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort. J Gerontol A Biol Sci Med Sci. 2020 Jul 20;glaa183. https://doi.org/10.1093/gerona/glaa183 Epub ahead of print. PMID: 32687551
42. Giorgi Rossi P, Marino M, Formisano D, et al. Reggio Emilia COVID-19 Working Group. Characteristics and outcomes of a cohort of COVID-19 patients in the Province of Reggio Emilia, Italy. PLoS One. 2020 Aug 27; 15(8):e0238281. https://doi.org/10.1371/journal.pone.0238281 PMID: 32853230

43. Tenforde MW, Billig Rose E, Lindsell CJ, et al. CDC COVID-19 Response Team. Characteristics of Adult Outpatients and Inpatients with COVID-19—11 Academic Medical Centers, United States, March-May 2020. MMWR Morb Mortal Wkly Rep. 2020 Jul 3; 69(26):841–846. https://doi.org/10.15585/mmwr.mm6926e3 PMID: 32614810

44. Harris PA, Taylor R, Minor BL, et al. REDCap Consortium. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019 Jul; 95:103208. https://doi.org/10.1016/j.jbi.2019.103208 Epub 2019 May 9. PMID: 31079660

45. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr; 42(2):377–81. https://doi.org/10.1016/j.jbi.2008.09.010 Epub 2008 Sep 30. PMID: 18929686

46. Weiskopf NG, Cohen AM, Hannan J, et al. Towards augmenting structured EHR data: a comparison of manual chart review and patient self-report. AMIA Annu Symp Proc. 2020 Mar 4; 2019:903–912. PMID: 32308887

47. R Core Team. R: A language and environment for statistical computing. Version 3.6.3 [software]. R Foundation for Statistical Computing. 2020 [cited 2020 August 18]. Available from: http://www.R-project.org/

48. Bergman J, Ballin M, Nordström A, Nordström P. Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: a nationwide study. Eur J Epidemiol. 2021 Mar; 36 (3):287–298. https://doi.org/10.1007/s10654-021-00732-w Epub 2021 Mar 11. PMID: 33704634

49. Montecino-Rodriguez E, Berent-Maoz B, Dorshkind K. Causes, consequences, and reversal of immune system aging. J Clin Invest. 2013 Mar; 123(3):958–65. https://doi.org/10.1172/JCI64096 Epub 2013 Mar 1. PMID: 23454758

50. Centers for Disease Control and Prevention. Flu & People 65 Years and Older. Accessed at https://www.cdc.gov/flu/highrisk/65over.htm on 31 August 2020.

51. Channappanavar R, Fett C, Mack M, et al. Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection. J Immunol. 2017 May 15; 198(10):4046–4053. https://doi.org/10.4049/jimmunol.1601896 Epub 2017 Apr 3. PMID: 28373583

52. Lee N, Lui GC, Wong KT, et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis. 2013 Oct; 57(8):1069–77. https://doi.org/10.1093/cid/cit471 Epub 2013 Jul 21. PMID: 23876395

53. Kalligeros M, Shehadeh F, Mylona EK, et al. Association of Obesity with Disease Severity Among Patients with Coronavirus Disease 2019. Obesity (Silver Spring). 2020 Jul; 28(7):1200–1204. https://doi.org/10.1002/oby.22859 Epub 2020 Jun 12. PMID: 32352637

54. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report. National Institutes of Health. 1998 September. https://www.nhlbi.nih.gov/files/docs/guidelines/ob_gdlns.pdf

55. Alamri F, Alsofayan Y, AI-Ruthia Y, et al. Predictors of Hospitalization Among Older Adults with COVID-19 in Saudi Arabia: A Cross-Sectional Study of a Nationally Representative Sample. Risk Manag Healthc Policy. 2021 Mar 3; 14:875–886. https://doi.org/10.2147/RMHP.S294786 PMID: 33692640

56. Alali AS, Alshehri AO, Assiri A, et al. Demographics, comorbidities, and outcomes among young and middle-aged COVID-19 patients in Saudi Arabia. Saudi Pharm J. 2021 Jun 19. https://doi.org/10.1016/j.jsps.2021.06.005 Epub ahead of print. PMID: 34177315

57. Simons D, Shahab L, Brown J, Perski O. The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). Addiction. 2021 Jun; 116(6):1319–1368. https://doi.org/10.1111/add.15276 Epub 2020 Nov 17. PMID: 33007104

58. Saurabh S, Verma MK, Gautam V, et al. Tobacco, alcohol use and other risk factors for developing symptomatic COVID-19 vs asymptomatic SARS-CoV-2 infection: a case-control study from western Rajasthan, India. Trans R Soc Trop Med Hyg. 2021 Jul 1; 115(7):820–831. https://doi.org/10.1093/trstmh/traa172 PMID: 33444432

59. Meini S, Fortini A, Andreini R, Scehi LA, Tascini C. The Paradox of the Low Prevalence of Current Smokers Among Covid-19 Patients Hospitalized in Non-Intensive Care Wards: Results From an Italian Multicenter Case-Control Study. Nicotine Tob Res. 2020 Sep 23:ntaa188. https://doi.org/10.1093/ntr/ntaa188 Epub ahead of print. PMID: 32964233

60. Colaneri M, Novelli V, Cutti S, et al. The experience of the health care workers of a severely hit SARS-CoV-2 referral Hospital in Italy: incidence, clinical course and modifiable risk factors for COVID-19.
61. Xie J, Zu Y, Alkhatib A, et al. Metabolic Syndrome and COVID-19 Mortality Among Adult Black Patients in New Orleans. Diabetes Care. 2020 Aug 25;dc201714. https://doi.org/10.2337/dc20-1714 Epub ahead of print. PMID: 32843337

62. Adams ML, Katz DL, Grandpre J. Population-Based Estimates of Chronic Conditions Affecting Risk for Complications from Coronavirus Disease, United States. Emerg Infect Dis. 2020 Aug; 26(8):1831–1833. https://doi.org/10.3201/eid2608.200679 Epub 2020 Apr 23. PMID: 32324118

63. Centers for Disease Control and Prevention. Overweight & Obesity: Adult Obesity Maps. 2009. Accessed at https://www.cdc.gov/obesity/data/prevalence-maps.html on 17 August 2020.

64. Yancy CW. COVID-19 and African Americans. JAMA. 2020 Apr 15. https://doi.org/10.1001/jama.2020.6548 Epub ahead of print. PMID: 32293639

65. United States Census Bureau. QuickFacts Colorado. 2019. Accessed at https://www.census.gov/quickfacts/CO on 17 August 2020.

66. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16; 181(2):271–280. e8. https://doi.org/10.1016/j.cell.2020.02.052 Epub 2020 Mar 5. PMID: 32142651

67. Vaduganathan M, Vardeny O, Michel T, et al. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020 Apr 23; 382(17):1653–1659. https://doi.org/10.1056/NEJMsr2005760 Epub 2020 Mar 30. PMID: 32277660

68. Golpe R, Pérez-de-Llano LA, Dalac D, et al. Lugo Covid-19 team. Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors. Med Clin (Barc). 2020 Dec 11; 155(11):488–490. https://doi.org/10.1016/j.medcli.2020.06.013 Epub 2020 Jun 25. PMID: 32651067

69. Schimmel J, Manini AF. Opioid Use Disorder and COVID-19: Biological Plausibility for Worsened Outcomes. Subst Use Misuse. 2020; 55(11):1900–1901. https://doi.org/10.1080/10826084.2020.1791184 Epub 2020 Jul 12. PMID: 32657207

70. O’Donnell J, Gladden RM, Mattson CL, et al. Vital Signs: Characteristics of Drug Overdose Deaths Involving Opioids and Stimulants—24 States and the District of Columbia, January-June 2019. MMWR Morb Mortal Wkly Rep. 2020 Sep 4; 69(35):1189–1197. https://doi.org/10.15585/mmwr.mm6935a1 PMID: 32881854

71. Sahyoun NR, Maynard LM, Zhang XL, et al. Factors associated with errors in self-reported height and weight in older adults. J Nutr Health Aging. 2008 Feb; 12(2):108–15. https://doi.org/10.1007/BF02982562 PMID: 18264637